公开(公告)号：US09161685B2

公开(公告)日：2015-10-20

申请号：US14110824

申请日：2012-04-12

Applicant: Satoshi Shimada

Inventor： Satoshi Shimada

IPC: A61B3/02 ,  A61B3/00 ,  A61B3/024

CPC classification number: A61B3/0025 ,  A61B3/024

Abstract: The perimeter (2), which has a perimetry means (13) that measures the visual field of a test eye and outputs the results thereof as measurement results (MR), is configured by comprising: a measurement database memory (17) wherein multiple measurement results of previous visual field measurements are stored as a measurement database (MDB) in a form that is divided into a database (DB1) pertaining to normal eyes and a database (DB2) pertaining to eyes with glaucoma; a means (16) for assessing whether or not the measurement results (MR) for the test eye can be used as measurement results for normal eyes; and a means (15) that, when it is determined that the measurement results can be used as measurement results for normal eyes, adds the measurement results to the database (DB1) pertaining to normal eyes along with database search attribute data (data such as the subject's age, sex, race, visual acuity, refractive index, diagnosis, residence, date and time of examination, etc.).

Abstract translation: 具有测量测试眼视野并输出其作为测量结果（MR）的结果的周边（2）被配置为包括：测量数据库存储器（17），其中多个测量 以前的视野测量的结果作为测量数据库（MDB）存储为分为属于正常眼睛的数据库（DB1）和与青光眼有关的数据库（DB2）的形式; 用于评估测试眼睛的测量结果（MR）是否可以用作正常眼睛的测量结果的装置（16）; 以及当确定测量结果可以用作普通眼睛的测量结果时，将测量结果与数据库搜索属性数据（诸如 受试者的年龄，性别，种族，视力，折射率，诊断，住院，检查日期和时间等）。

公开(公告)号：US09138020B2

公开(公告)日：2015-09-22

申请号：US13522666

申请日：2011-01-24

Applicant: Kazuhiko Matsuo ,  Hidefumi Koga

Inventor： Kazuhiko Matsuo ,  Hidefumi Koga

IPC: A61F13/00 ,  A41D13/06 ,  A61F13/14 ,  A61F13/08 ,  A61F2/68 ,  A61F5/01 ,  A61F2/76

CPC classification number: A41D13/065 ,  A61F2/68 ,  A61F5/0109 ,  A61F5/0123 ,  A61F13/00 ,  A61F13/08 ,  A61F13/14 ,  A61F2002/7645 ,  A61F2210/0057

Abstract: A knee joint supporter which can improve the stability of the knee joint, reduce the wearer's fatigue and reduce the load on the patellar tendon includes a first anchor section formed by wrapping one end of a tubular knitted fabric around the wearer's thigh to tighten it with the fabric, a second anchor section formed by wrapping the other end of the fabric around the wearer's lower thigh to tighten it with the fabric, and a substantially U-shaped knitted supporting section joined to the first anchor section, covering the wearer's patella region and thus supporting the wearer's patella. In the circumferential direction of the fabric, the stretch resistance of the two anchor parts are larger than the stretch resistance of a base fabric section. In the length width direction of the fabric, the stretch resistance of the supporting section is larger than the stretch resistance of the base fabric section.

Abstract translation: 可以提高膝关节的稳定性的膝关节支撑件，减少佩戴者的疲劳并减轻髌骨腱上的负荷，包括通过将管状针织物的一端围绕穿戴者的大腿缠绕而形成的第一锚定部， 织物，通过将织物的另一端缠绕在穿戴者的下大腿上以将其与织物收紧而形成的第二锚定部分，以及连接到第一锚固部分的覆盖穿着者髌骨区域的大致U形的针织支撑部分，因此 支持佩戴者的髌骨。 在织物的圆周方向上，两个锚固部件的拉伸阻力大于基布部分的拉伸阻力。 在织物的长度方向上，支撑部的拉伸阻力大于基布部的拉伸阻力。

公开(公告)号：US09089260B2

公开(公告)日：2015-07-28

申请号：US13817603

申请日：2011-08-08

Applicant: Takuya Hara

Inventor： Takuya Hara

IPC: A61B3/10 ,  A61B3/00 ,  A61B3/14 ,  F21V21/28

CPC classification number: A61B3/0091 ,  A61B3/0075 ,  A61B3/14 ,  F21V21/28

Abstract: [Problem] To increase, compared to conventional devices, the range of motion of the light emitter (fixation lamp) in an external fixation lamp for an ophthalmological instrument and allow movement of the light emitter to arbitrary positions.[Solution] The fixation lamp (1) has a first arm (A1), which supports a light emitter (2) and is supported by a second arm (A2) via a first joint (C1), and is configured so that the first arm (A1) is able to revolve around at least two axes of revolution (E1, E2) by means of the first joint (C1) and said axes of rotation (E1, E2) are not disposed on the same line. Thereby, the range in which the light emitter (2) can be moved can be increased compared to conventional devices and the light emitter can be moved to an arbitrary position in an arbitrary direction.

Abstract translation: [问题]与传统装置相比，增加用于眼科仪器的外部固定灯中的光发射器（固定灯）的运动范围并允许光发射器移动到任意位置。 [解决方案]固定灯（1）具有第一臂（A1），其支撑发光体（2），并且经由第一接头（C1）由第二臂（A2）支撑，并且被构造成使得第一 臂（A1）能够通过第一接头（C1）绕至少两个旋转轴线（E1，E2）旋转，并且所述旋转轴线（E1，E2）不设置在同一直线上。 由此，与以往的装置相比，可以使发光体（2）能够移动的范围增大，能够使发光体向任意方向移动到任意位置。

公开(公告)号：US20150196538A1

公开(公告)日：2015-07-16

申请号：US14429449

申请日：2013-09-27

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397

CPC classification number: A61K31/423 ,  A61K31/397 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

Abstract translation: 本发明涉及提供用于预防和/或治疗诸如动脉粥样硬化，高胆固醇血症，包括人在内的哺乳动物中的低HDL血液病的血脂异常状况的药物组合组合物和药物组合的问题。 一种用于预防和/或治疗血脂异常等的药物组合物，其包含（a）由通式（1）表示的化合物（式中各符号与说明书中所定义的相同）或其盐 或其溶剂合物和（b）胆固醇吸收抑制剂。

公开(公告)号：US09028065B2

公开(公告)日：2015-05-12

申请号：US13575635

申请日：2011-01-21

Applicant: Norihiko Yokoi ,  Yutaka Mizukusa ,  Shigeru Kinoshita

Inventor： Norihiko Yokoi ,  Yutaka Mizukusa ,  Shigeru Kinoshita

IPC: A61B3/10

CPC classification number: A61B3/101

Abstract: A ophthalmologic method and apparatus for processing a captured image of a tear film lipid layer on a cornea of a patient's eye to be examined and for classifying types of dry eye of the patient's eye. The captured image of the tear film lipid layer is processed to measure a movement speed of the tear film lipid layer at the time of opening of the patient's eyelid. The captured image of the tear film lipid layer is further processed to measure a time until the tear film lipid layer is broken up after the patient's eyelid has been opened and a break up region is detected. The type of dry eye of the patient's eye is classified based on the two measurement results.

Abstract translation: 一种眼科方法和装置，用于处理待检查的患者眼睛的角膜上的泪膜脂质层的捕获图像，以及用于分类患者眼睛的干眼的类型。 处理泪膜脂质层的捕获图像以测量打开患者眼睑时泪液脂质层的移动速度。 进一步处理泪膜脂质层的拍摄图像，以测量在患者的眼皮已经打开并且检测到分离区域之后眼泪膜脂质层破裂的时间。 根据两个测量结果对患者眼睛的干眼症状进行分类。

公开(公告)号：US20140378441A1

公开(公告)日：2014-12-25

申请号：US14481467

申请日：2014-09-09

Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION ,  KOWA COMPANY, LTD.

Inventor： Tatsuro Ishibashi ,  Shintaro Nakao ,  Ryoichi Arita ,  Ken Mizuno ,  Akifumi Tsuchiura

IPC: A61K31/551 ,  A61K9/00

CPC classification number: A61K31/551 ,  A61K9/0046 ,  A61K9/0048 ,  A61K31/496 ,  A61K47/10 ,  C07D401/12

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

Abstract translation: 本文公开了眼底疾病，特别是糖尿病性视网膜病变或年龄相关性黄斑变性的预防或治疗剂。 眼底疾病的预防或治疗剂包括：（S） - （ - ） - 1-（4-氟-5-异喹啉磺酰基）-2-甲基-1,4-高哌嗪，其盐或其溶剂合物， 作为活性成分。

公开(公告)号：US08906895B2

公开(公告)日：2014-12-09

申请号：US13700849

申请日：2011-06-03

Applicant: Tadaaki Ohgiya ,  Takeshi Murakami ,  Katsutoshi Miyosawa ,  Kimiyuki Shibuya ,  Koichi Yamazaki ,  Taichi Kusakabe

Inventor： Tadaaki Ohgiya ,  Takeshi Murakami ,  Katsutoshi Miyosawa ,  Kimiyuki Shibuya ,  Koichi Yamazaki ,  Taichi Kusakabe

IPC: A61K31/495 ,  C07D239/48 ,  C07D239/47

CPC classification number: C07D239/47

Abstract: Substantially optically pure (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid, or a salt thereof, or a solvate thereof, which has actions of reducing amount of PCSK9 protein and increasing amount of LDL receptor.

Abstract translation: 基本上光学纯的（S） - 反 - {4 - [（{2 - [（{1- [3,5-双（三氟甲基）苯基]乙基} {5- [2-（甲基磺酰基）乙氧基] 吡啶-3-基}氨基）甲基] -4-（三氟甲基）苯基}（乙基）氨基）甲基]环己基}乙酸或其盐或其溶剂合物，其具有减少PCSK9蛋白量和增加LDL量的作用 受体。

公开(公告)号：US08791090B2

公开(公告)日：2014-07-29

申请号：US13256549

申请日：2010-03-31

Applicant: Masanori Ashikawa ,  Junya Tagashira ,  Akiyasu Koketsu ,  Toshiharu Morimoto ,  Takahiro Kitamura ,  Syunji Takemura ,  Gen Watanabe ,  Tatsuaki Nishiyama ,  Satoshi Goda ,  Masaki Yamabi ,  Takeshi Doi ,  Hiroyuki Ishiwata

Inventor： Masanori Ashikawa ,  Junya Tagashira ,  Akiyasu Koketsu ,  Toshiharu Morimoto ,  Takahiro Kitamura ,  Syunji Takemura ,  Gen Watanabe ,  Tatsuaki Nishiyama ,  Satoshi Goda ,  Masaki Yamabi ,  Takeshi Doi ,  Hiroyuki Ishiwata

IPC: A01N57/00 ,  A61K31/385

CPC classification number: C07D215/42 ,  A61K31/47 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/69 ,  C07D215/233 ,  C07D215/44 ,  C07D215/46 ,  C07D215/48 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12

Abstract: Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R1, R2, R2′, R3 and R3′ independently represent a hydrogen atom, a C1-6 alkyl group, or the like; R4, R5, R6, R7, R8, R9 and R10 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or the like; A represents N—R11, a sulfur atom, or an oxygen atom; R11 represents a hydrogen atom, a C1-6 alkyl group, or the like; B represents a C6-14 aryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.

Abstract translation: 公开了具有低分子量且具有增强EPO产生活性和/或提高血红蛋白生成活性的化合物。 具体公开的是EPO生产增强剂和/或包含1-酰基-4-（取代的氧基，取代的氨基或取代的硫代）-1,2,3,4-四氢喹啉衍生物，更具体地是四氢喹啉化合物的血红蛋白生成增强剂 由通式（1）表示[其中R1，R2，R2'，R3和R3'独立地表示氢原子，C1-6烷基等; R 4，R 5，R 6，R 7，R 8，R 9和R 10独立地表示氢原子，卤素原子，C 1-6烷基等; A表示N-R11，硫原子或氧原子; R 11表示氢原子，C 1-6烷基等; B表示C 6-14芳基或5至10元杂环基; n表示0或1的整数]，四氢喹啉化合物的盐或四氢喹啉化合物或其盐的溶剂合物。

公开(公告)号：US08778954B2

公开(公告)日：2014-07-15

申请号：US13394266

申请日：2010-09-29

Applicant: Toru Miura ,  Seiichi Sato ,  Hajime Yamada ,  Junya Tagashira ,  Ryohei Sekimoto ,  Rie Ishida ,  Hitomi Aoki ,  Tadaaki Ohgiya

Inventor： Toru Miura ,  Seiichi Sato ,  Hajime Yamada ,  Junya Tagashira ,  Ryohei Sekimoto ,  Rie Ishida ,  Hitomi Aoki ,  Tadaaki Ohgiya

IPC: C07D401/14 ,  A61K31/422 ,  A61K31/4427

CPC classification number: C07D401/14 ,  A61K31/422 ,  A61K31/4427 ,  C07D413/14

Abstract: Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPARγ-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound. Specifically disclosed are: a compound represented by general formula (I) (wherein the ring A represents a pyridine ring; the ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents a C1-6 alkyl group; R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group; and R3, R4, R5 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo-C1-6 alkyl group, or a C1-6 alkoxy group which may have a substituent), a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition containing the compound, the salt or the solvate.

Abstract translation: 公开了一种对血管紧张素II受体具有拮抗作用和PPARγ活化活性的新型化合物，因此可用作高血压，心脏病，动脉硬化，2型糖尿病，糖尿病并发症的预防和/或治疗剂 ，代谢综合征等; 和含有该化合物的药物组合物。 具体公开的是：由通式（I）表示的化合物（其中环A表示吡啶环;环B表示四唑环或恶二唑-5（4H） - 酮环; X表示C-R5或氮 原子; R1表示C1-6烷基; R2表示C1-6烷基或C3-8环烷基; R3，R4，R5分别表示氢原子，卤素原子，C1-6烷基， 卤代C 1-6烷基或可具有取代基的C 1-6烷氧基），化合物的盐或化合物或其盐的溶剂合物; 和含有该化合物，该盐或溶剂化物的药物组合物。

公开(公告)号：US08673976B2

公开(公告)日：2014-03-18

申请号：US13524134

申请日：2012-06-15

Applicant: Yuji Yoshikawa ,  Megumi Yamamoto ,  Naoto Ishibashi ,  Mami Seki

Inventor： Yuji Yoshikawa ,  Megumi Yamamoto ,  Naoto Ishibashi ,  Mami Seki

IPC: A01N37/00

CPC classification number: A61K31/201

Abstract: A medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis, which comprises a polyprenyl compound (e.g., 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) as an active ingredient.

Abstract translation: 一种用于预防和/或治疗肝脂肪变性或非酒精性脂肪性肝炎的药物，其包含聚异戊二烯基化合物（例如3,7,11,15-四甲基-2,4,6,10,14-十六碳五烯酸）作为 活性成分。